ThromboGenics NV : ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)
(Thomson Reuters ONE) -
Leuven, Belgium, 18(th) September, 2017 - ThromboGenics NV (Euronext Brussels:
THR), a biotechnology company developing novel treatments for retinal disorders,
with a focus on diabetic eye disease, announced today that it will regain full
global rights to JETREA® from Alcon, a Novartis company, based on a mutual
agreement that the unique characteristics of JETREA make Thrombogenics a better
fit for building a sustainable long-term niche business.
JETREA is the first and only approved pharmacological treatment for symptomatic
vitreomacular adhesion (VMA) in the US and vitreomacular traction (VMT) in
Europe and elsewhere in the world. First introduced in 2013, JETREA has been
approved in 54 countries worldwide, with nearly 30,000 patients being treated in
about 20 countries.
Under the terms of the agreement, Alcon and Novartis will work closely with
ThromboGenics to ensure continuity and access to JETREA for existing and future
customers.
Patrik De Haes, MD, CEO of ThromboGenics nv, said "We are pleased to have
reached this agreement with Alcon and Novartis in relation to the non-US rights
to JETREA. We intend to take time to evaluate how best to capitalize on the
global opportunity that we now have with JETREA. In the near term, it is our key
priority to secure the continuity of care by ensuring that patients and
physicians have timely access to this unique pharmacological treatment for
symptomatic vitreomacular adhesion/ traction (sVMA/VMT). We look forward to
working with Novartis during this important transition period."
Dr. De Haes continued, "We are also pleased to welcome Novartis as a shareholder
in ThromboGenics as we are developing our pipeline of novel treatments for
diabetic eye disease. The significant funds that we have received today will
allow ThromboGenics to develop its pipeline of novel disease-modifying drug
candidates which are targeting all of the key segments of the diabetic eye
disease market."
Under the terms of the agreement, ThromboGenics receives a cash amount of ?53.7
million and a forthcoming equity investment of ?10 million in ThromboGenics
capital.
Following the agreements announced today, ThromboGenics will have over ?120
million in cash.
- END -
For further information please contact:
+----------------------------------------+-------------------------------------+
|ThromboGenics |Citigate Dewe Rogerson |
| |David Dible/ Sylvie Berrebi/ Isabelle|
|Wouter Piepers, Global Head of Corporate|Andrews |
|Communications & IR |Tel: +44 20 7282 9571 |
| |thrombogenics(at)citigatedr.co.uk |
|+32 16 75 13 10 / +32 478 33 56 32 | |
| | |
|wouter.piepers(at)thrombogenics.com | |
+----------------------------------------+-------------------------------------+
About ThromboGenics
ThromboGenics is a biopharmaceutical company focused on developing innovative
treatments for eye disease, with a focus on diabetic eye disease. The company's
pipeline of disease modifying drug candidates is targeting the key segments of
the diabetic eye disease market.
ThromboGenics is conducting a Phase IIa clinical trial evaluating multiple doses
of THR-409 (ocriplasmin) to induce a total Posterior Vitreous Detachment in
patients with Non-Proliferative Diabetic Retinopathy (NPDR).
ThromboGenics is conducting a Phase II clinical study evaluating THR- 317, a
PLGF inhibitor for the treatment of diabetic macular edema, as a stand-alone or
as a combination therapy with anti-VEGF treatments. In addition, THR-149, a
plasma kallikrein inhibitor, which has resulted from research collaboration with
Bicycle Therapeutics, and THR-687, an integrin antagonist, which was in-licensed
from Galapagos, are in late stage pre-clinical development.
ThromboGenics pioneered a new drug category of pharmacological vitreolysis with
JETREA® (ocriplasmin) which is now approved for the treatment of symptomatic
vitreomacular traction in 54 countries worldwide. ThromboGenics is
headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels
exchange under the symbol THR.
More information is available at www.thrombogenics.com
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking".
Such forward-looking statements are based on current expectations, and,
accordingly, entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events or any other reason. Additional information concerning risks and
uncertainties affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is contained in
the Company's Annual Report. This press release does not constitute an offer or
invitation for the sale or purchase of securities or assets of ThromboGenics in
any jurisdiction. No securities of ThromboGenics may be offered or sold within
the United States without registration under the U.S. Securities Act of 1933, as
amended, or in compliance with an exemption therefrom, and in accordance with
any applicable U.S. state securities laws.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ThromboGenics NV via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 18.09.2017 - 07:30 Uhr
Sprache: Deutsch
News-ID 560155
Anzahl Zeichen: 6798
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 285 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ThromboGenics NV : ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)"
steht unter der journalistisch-redaktionellen Verantwortung von
ThromboGenics NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
